Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Spinal Cord Injury Research Grant

    Forecasted

    Spinal Cord Injury Research Grant supports researchers studying innovative treatment and rehabilitation techniques to improve function for people with spinal cord injuries.

    Browse similar grants
    Cancer Research Grants 2026

    Funder: Pennsylvania CURE (Commonwealth Universal Research Enhancement)

    Due Dates (Anticipated): November 2026 (Application deadline) | September 2027 (Letters of Intent deadline)

    Funding Amounts: $2,450,030.08 available for three to six anticipated awards under RFA #67-203; published term July 1, 2026–June 30, 2030

    Summary: Supports innovative spinal cord injury research on treatment and rehabilitation techniques to improve function for people with spinal cord injuries.

    Key Information: Human-subjects research funded by the Department of Health requires review by its Institutional Review Board.


    Description

    Pennsylvania’s Commonwealth Universal Research Enhancement (CURE) program supports spinal cord injury research through the Department of Health’s Health Research Office. RFA #67-203 seeks to foster innovative research into treatment and rehabilitative techniques, with the overall objective of improving function for people with spinal cord injuries.

    CURE was authorized by Act 2001-77, the Tobacco Settlement Act, as a state health research program supporting clinical, health services, and biomedical research. It awards both noncompetitive formula grants and competitive non-formula grants issued through Requests for Applications. This spinal cord injury opportunity is administered within that broader research framework, with program oversight informed by the Health Research Advisory Committee and, for spinal cord work, the Spinal Cord Research Advisory Committee.


    Atom

    See the full grant listing

    Sign in to view full eligibility details, sources, similar grants, and AI-powered analysis.